ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 219 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,222,713 | -3.0% | 679,459 | +25.5% | 1.31% | -2.0% |
| Q2 2023 | $24,978,472 | +1.0% | 541,480 | -12.2% | 1.34% | +28.0% |
| Q1 2023 | $24,720,848 | -34.7% | 616,480 | -24.6% | 1.04% | -34.3% |
| Q4 2022 | $37,859,532 | +928.0% | 817,171 | +818.8% | 1.59% | +939.2% |
| Q3 2022 | $3,683,000 | -82.3% | 88,940 | -74.5% | 0.15% | -80.7% |
| Q2 2022 | $20,793,000 | -45.5% | 348,519 | -33.6% | 0.79% | -32.1% |
| Q1 2022 | $38,133,000 | -6.5% | 525,100 | +8.2% | 1.16% | +47.5% |
| Q4 2021 | $40,804,000 | – | 485,242 | – | 0.79% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |